With numerous imipenem-resistant clinical isolates of Pseudomonas aeruginosa as well as in vitro-selected resistant mutants, we have demonstrated, by a simple method with a powerful cephalosporinase inhibitor, BRL42715, the contribution of chromosomal cephalosporinase in resistance to imipenem in this species.
It has previously been very well demonstrated with Pseudomonas aeruginosa that resistance to imipenem is generally due to decreased expression of the outer membrane protein D2 (1, 6) , which allows facilitated diffusion of carbapenems (9) .
We have previously demonstrated (3) that resistance to imipenem in Enterobacter cloacae was due to an association of decreased permeability and high-level production of cephalosporinase. Thus, it was tempting to demonstrate by a simple method, i.e., inhibition of cephalosporinase with a P-lactamase inhibitor, a similar mechanism in numerous clinical isolates of P. aeruginosa resistant to carbapenems. This hypothesis was recently tested with laboratory mutants and with a few clinical isolates by different approaches (4, 8) .
Forty-three clinical isolates of imipenem-resistant P. aeruginosa (for which MICs were >4 ,ug/ml) were collected during a 1-year period in two hospitals from different units and different patients. Imipenem-resistant strains were also selected in vitro from imipenem-susceptible clinical isolates on 16 ,ug of imipenem per ml. All strains were grown with aeration at 37°C in brain heart infusion broth (Difco). The MICs of antibiotics were determined on brain heart infusion agar with a multiple-inoculum replicator, with ca. 104 CFU per spot. MICs of imipenem were determined either alone or in the presence of a fixed concentration of the different inhibitors (4 ,ug/ml determined with increasing concentrations of the different inhibitors and by testing residual hydrolysis of cephaloridine after 10 min of incubation with the inhibitor. P-Lactamases were also assessed in intact cells as follows: after incubation (0 to 2 h) with different antibiotics, 5 ml of cells was washed three times in phosphate buffer (50 mM, pH 7, containing 5 mM Mg2") at 4°C, resuspended in 1 ml of buffer, sonified, and centrifuged (100,000 x g) before the P-lactamase activity was assayed. Outer membranes were prepared with 0.3% (wt/vol) N-laurylsarcosine as described previously (2) . Outer membrane proteins were separated on sodium dodecyl sulfate-containing polyacrylamide (13%) gels.
MICs of imipenem in the presence of 4 ,ug of the different inhibitors of P-lactamases per ml are presented in Since the MIC of BRL42715 alone was higher than 128 ,ug/ml for these strains, it was conceivable that the inhibition by the inhibitor of the ,-lactamase present in the P. aeruginosa strain was responsible for the decreased MICs. To test this hypothesis, outer membranes, 3-lactamase activities, and inhibition by the inhibitor of I-lactamases were examined with eight imipenem-resistant strains, five of which were derivatives obtained in vitro; the three remaining strains were obtained in vivo during imipenem therapy. As shown in Fig. 1 , all of these derivatives lacked the porin D2. In the presence of BRL42715, no reappearance of this protein was observed in the resistant strains (data not shown). In all of these strains, even after induction, only one ,B-lactamase, with a pI of between 7.4 and 7.6, was present.
In all but three cases, the ,-lactamase was inducible; in three strains, the 13-lactamase was constitutive and was present at a high level in the absence of induction (Table 2) . Very similar ,3-lactamase activities were observed before or after induction for the corresponding imipenem-sensitive strains not lacking the D2 porin (data not shown). For all of these strains, in the presence of 4 ,ug of BRL42715 per ml, MICs of imipenem and meropenem were decreased 4-to 16-fold and 1-to 4-fold, respectively ( (3, 7) , and it was more recently demonstrated with P. aeruginosa (4, 8) . In this study, we used an inhibitor of f-lactamase which decreases the cephalosporinase activity. This was done to prove directly with clinical imipenemresistant isolates and in vitro mutants of P. aeruginosa that cephalosporinase, either induced by imipenem or constitutively expressed, was part of the mechanism of resistance to the carbapenems. BRI42715, which was at least 1,000-fold more active than sulbactam or tazobactam against the P. aeruginosa cephalosporinase, was the only inhibitor (at 4 ug/ml) which gave 4-to 16-fold decreased MICs of imipenem for the resistant clinical isolates as well as for the in vitro mutants. With the eight resistant strains for which outer membrane protein profiles were studied, as expected, the resistance was also associated with a lack of the D2 porin (1, 6, 9) .
Interestingly, the decrease in the MICs of meropenem in the presence of BRL42715 was lower than that observed for imipenem. This is reminiscent of the results obtained with in vitro mutants of P. aeruginosa for which, in contrast to results with imipenem, there was only a very moderate decrease in the MICs of meropenem when the loss of porin D2 was associated with a low-level expression of noninducible cephalosporinase (4, 8) . This could be explained by the apparent better stability of meropenem in the presence of class I enzymes (10) .
Finally, since BRL42715 is a very good inhibitor of cephalosporinase (11) , it could be used as a probe to test, with different species, the role of cephalosporinase as the mechanism of resistance or as a complementary mechanism necessary to express resistance to different 3-lactam antibiotics. This is comparable to the method used in a study of carbapenem-resistant E. cloacae strains in which the role of cephalosporinase as an adjunct to decreased outer membrane permeability was established for this type of resistance after the introduction of the ampD gene which repressed cephalosporinase production (3) . 37, 1993 
